Innovation

  1. Home
  2. Innovation
Safe and active advanced T cell therapies

We apply our broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eradicate these cancer cells.

CAR T cell therapies

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the t cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Find out more

Pipeline Products

Our next generation, programmed T cell therapies in development.

Learn more

Advanced cell programming technology

Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.

Read more

Manufacturing

We manufacture our product candidates and commercial supply in the UK.

Learn more

Latest Abstracts & Publications

See all
New England Journal of Medicine
November 27 2024

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Nature Medicine
November 11 2024

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

Blood
August 30 2023

CD19/CD22 targeting with co-transduced CAR T-cells to prevent antigen negative relapse after CAR T-cell therapy of B-ALL

Chimeric Antigen Receptor T Cell therapy
Advanced cell programming